Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia
Fuente:
Redalyc
Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Universidad del Valle
2012
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1876448203510906880 |
|---|---|
| author | Gonzalo Guevara |
| author_facet | Gonzalo Guevara |
| contents | Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia Gonzalo Guevara Medicina BCR ABL imatinib Philadelphia chromosome minimal residual disease Objective: To evaluate the hematological, cytogenetic, and molecular responses in Colombian patients with CML chronic myeloid leukemia (CML) treated with imatinib. Methods: Two groups of patients, one with the novo diagnostic and another in state of complete cytogenetic remission were followed for 12 months with quantitative PCR evaluations every three months and with chromosomal analysis every 6 months. Results: The group with the novo diagnosis showed 50% of complete cytogenetic remission at 12 months while the other 50% were considered to have primary resistance. Respect the molecular analysis, 10.5% of the patients reached undetectable BCR-ABL transcripts at 12 months. In the complete cytogenetic remission group, 10.6% lost the state of complete cytogenetic remission at 12 months, 50% reached undetectable BCR-ABL transcripts but 10% showed levels higher than 10%, which in our standardization was equal to no molecular response. Conclusions: Despite having received the conventional dosages of 400 mg/day of imatinib, the cytogenetic and molecular responses obtained in our group of Colombian patients with CML, were lower than those in other international studies. 2012 artículo científico 0120-8322 https://www.redalyc.org/articulo.oa?id=28324856004 https://www.redalyc.org/journal/283/28324856004/ https://www.redalyc.org/journal/283/28324856004/html/ https://www.redalyc.org/journal/283/28324856004/28324856004.epub https://www.redalyc.org/journal/283/28324856004/movil en http://www.redalyc.org/revista.oa?id=283 Colombia Médica application/pdf Universidad del Valle Colombia Médica (Colombia) Num.4 Vol.43 |
| format | Artículo científico |
| id | redalyc_28324856004 |
| institution | Redalyc |
| language | en |
| publishDate | 2012 |
| publisher | Universidad del Valle |
| spellingShingle | Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia Gonzalo Guevara Medicina BCR ABL imatinib Philadelphia chromosome minimal residual disease Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia Gonzalo Guevara Medicina BCR ABL imatinib Philadelphia chromosome minimal residual disease Objective: To evaluate the hematological, cytogenetic, and molecular responses in Colombian patients with CML chronic myeloid leukemia (CML) treated with imatinib. Methods: Two groups of patients, one with the novo diagnostic and another in state of complete cytogenetic remission were followed for 12 months with quantitative PCR evaluations every three months and with chromosomal analysis every 6 months. Results: The group with the novo diagnosis showed 50% of complete cytogenetic remission at 12 months while the other 50% were considered to have primary resistance. Respect the molecular analysis, 10.5% of the patients reached undetectable BCR-ABL transcripts at 12 months. In the complete cytogenetic remission group, 10.6% lost the state of complete cytogenetic remission at 12 months, 50% reached undetectable BCR-ABL transcripts but 10% showed levels higher than 10%, which in our standardization was equal to no molecular response. Conclusions: Despite having received the conventional dosages of 400 mg/day of imatinib, the cytogenetic and molecular responses obtained in our group of Colombian patients with CML, were lower than those in other international studies. 2012 artículo científico 0120-8322 https://www.redalyc.org/articulo.oa?id=28324856004 https://www.redalyc.org/journal/283/28324856004/ https://www.redalyc.org/journal/283/28324856004/html/ https://www.redalyc.org/journal/283/28324856004/28324856004.epub https://www.redalyc.org/journal/283/28324856004/movil en http://www.redalyc.org/revista.oa?id=283 Colombia Médica application/pdf Universidad del Valle Colombia Médica (Colombia) Num.4 Vol.43 |
| title | Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia |
| topic | Medicina BCR ABL imatinib Philadelphia chromosome minimal residual disease |
| url | https://www.redalyc.org/articulo.oa?id=28324856004 https://www.redalyc.org/journal/283/28324856004/ https://www.redalyc.org/journal/283/28324856004/html/ https://www.redalyc.org/journal/283/28324856004/28324856004.epub https://www.redalyc.org/journal/283/28324856004/movil |